{"cluster": 50, "subcluster": 34, "abstract_summ": "This Comment summarizes the key strategies that should be implemented for both patients and IBD specialists to provide optimal care while avoiding new outbreaks for the first 6\u201312 months after the peak of the COVID-19 pandemic.The coronavirus disease (COVID-19) worldwide outbreak has led to a dramatic challenge for all healthcare systems, including inflammatory bowel disease (IBD) centres.Here, we describe the fast changes and clinical issues that IBD specialists could face during this SARS-CoV-2 infection pandemic, highlighting the potential rearrangements of care and resetting of clinical priorities.I submit that attention to COVID-19 pharmacologic therapy needs similar emphasis, including identifying any existing medications that can be repurposed to treat COVID-19 patients.In this commentary, the authors explain and call for a broader use of outcome-adaptive randomization when designing clinical trials to test multiple COVID-19 interventions.", "title_summ": "Pharmacologic Therapy for COVID-19 InfectionCOVID-19 trials in Italy: A call for simplicity, top standards and global poolingMultigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions: What is the Link?The day after COVID-19 in IBD: how to go back to \u2018normal\u2019Management of IBD during the COVID-19 outbreak: resetting clinical prioritiesCOVID-19: A Brief Overview of the Discovery Clinical Trial.Optimizing COVID-19 candidate therapeutics: Thinking Without Borders.COVID-19 and Bacillus Calmette-Gu\u00e9rin", "title_abstract_phrases": "Management of IBD during the COVID-19 outbreak: resetting clinical prioritiesThe coronavirus disease (COVID-19) worldwide outbreak has led to a dramatic challenge for all healthcare systems, including inflammatory bowel disease (IBD) centres.Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) InterventionsIn this commentary, the authors explain and call for a broader use of outcome-adaptive randomization when designing clinical trials to test multiple COVID-19 interventions.This Comment summarizes the key strategies that should be implemented for both patients and IBD specialists to provide optimal care while avoiding new outbreaks for the first 6\u201312 months after the peak of the COVID-19 pandemic.I submit that attention to COVID-19 pharmacologic therapy needs similar emphasis, including identifying any existing medications that can be repurposed to treat COVID-19 patients.Pharmacologic Therapy for COVID-19 InfectionThe COVID-19 pandemic has focused attention on issues of epidemiology, public health, and vaccine design."}